GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Up 556.9% in December

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 90,000 shares, an increase of 556.9% from the December 15th total of 13,700 shares. Based on an average daily volume of 365,300 shares, the short-interest ratio is presently 0.2 days. Approximately 4.6% of the company’s stock are sold short.

Analyst Ratings Changes

Several research firms recently weighed in on GTBP. Roth Capital upgraded GT Biopharma to a “strong-buy” rating in a research report on Monday, December 2nd. Roth Mkm began coverage on GT Biopharma in a research report on Monday, December 2nd. They issued a “buy” rating and a $11.00 price objective on the stock.

GT Biopharma Trading Up 5.4 %

NASDAQ GTBP traded up $0.13 during trading hours on Tuesday, hitting $2.52. 114,125 shares of the company were exchanged, compared to its average volume of 536,828. The stock has a 50-day moving average price of $2.85 and a 200 day moving average price of $2.57. GT Biopharma has a 52 week low of $1.72 and a 52 week high of $10.66.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.